Search Results - "Balian, D"

  • Showing 1 - 18 results of 18
Refine Results
  1. 1

    Reproducibility of semi-quantitative assessment of aortic valve calcification and valve motion on echocardiography: a small-scale study by Balian, D, Koethe, B, Mohanty, S, Daaboul, Y, Mahrokhian, S H, Frankel, J, Li, J, Kherlopian, A, Downey, B C, Wessler, B

    Published in Echo research and practice (01-07-2024)
    “…Aortic stenosis (AS) is the most common degenerative valve disease in high income countries. While hemodynamic metrics are commonly used to assess severity of…”
    Get full text
    Journal Article
  2. 2

    Interspecies scaling: predicting clearance of drugs in humans. Three different approaches by Mahmood, I, Balian, J D

    Published in Xenobiotica (01-09-1996)
    “…1. The interspecies scaling approach to predict clearance in humans from animal data was tested for a wide variety of drugs. 2. Three different methods were…”
    Get more information
    Journal Article
  3. 3

    Pharmacokinetic and Pharmacodynamic Consequences of Metabolism-Based Drug Interactions with Alprazolam, Midazolam, and Triazolam by Yuan, Rae, Flockhart, David A., Balian, John D.

    Published in Journal of clinical pharmacology (01-11-1999)
    “…This review was conducted to identify the current data on drug interactions with alprazolam, midazolam, and triazolam to guide practitioners in the use of…”
    Get full text
    Journal Article
  4. 4

    The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study by Balian, J D, Sukhova, N, Harris, J W, Hewett, J, Pickle, L, Goldstein, J A, Woosley, R L, Flockhart, D A

    Published in Clinical pharmacology and therapeutics (01-06-1995)
    “…We compared omeprazole and mephenytoin as probes for the CYP2C19 metabolic polymorphism. Single oral doses of omeprazole (20 mg) or mephenytoin (100 mg) were…”
    Get more information
    Journal Article
  5. 5

    The pharmacokinetic principles behind scaling from preclinical results to phase I protocols by MAHMOOD, I, BALIAN, J. D

    Published in Clinical pharmacokinetics (1999)
    “…Extrapolation of animal data to assess pharmacokinetic parameters in humans is an important tool in drug development. Allometric scaling has many proponents,…”
    Get full text
    Journal Article
  6. 6

    In vitro metabolic interaction studies: Experience of the Food and Drug Administration by Yuan, Rae, Parmelee, Thomas, Balian, John D., Uppoor, Ramana S., Ajayi, Funmilayo, Burnett, Alfreda, Lesko, Larry J., Marroum, Patrick

    Published in Clinical pharmacology and therapeutics (01-07-1999)
    “…A total of 194 new molecular entities approved by the Food and Drug Administration between 1992 and 1997 were surveyed to determine the role of in vitro…”
    Get full text
    Journal Article
  7. 7

    Designing and implementing procurement requirements for carbon reduction in infrastructure construction - international overview and experiences by Kadefors, Anna, Lingegård, Sofia, Uppenberg, Stefan, Alkan-Olsson, Johanna, Balian, Daniel

    “…Carbon emissions emanating from infrastructure construction are substantial, and public infrastructure clients have begun to include carbon reduction goals in…”
    Get full text
    Journal Article
  8. 8

    Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance by Mahmood, I, Balian, J D

    Published in Journal of pharmaceutical sciences (01-04-1996)
    “…The objective of this study was to test the interspecies-scaling approach in a series of antiepileptic drugs. Clearance, volume of distribution, and…”
    Get more information
    Journal Article
  9. 9

    In vivo drug-drug interaction studies- A survey of all new molecular entities approved from 1987 to 1997 by Marroum, Patrick J., Uppoor, Ramana S., Parmelee, Thomas, Ajayi, Funmilayo, Burnett, Alfreda, Yuan, Rae, Svadjian, Raffi, Lesko, Lawrence J., Balian, John D.

    Published in Clinical pharmacology and therapeutics (01-09-2000)
    “…Ninety‐eight new molecular entities applications approved between 1987 to 1991 (period I) and 193 applications for new molecular entities between 1992 to 1997…”
    Get full text
    Journal Article
  10. 10

    Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype by Marinac, J S, Balian, J D, Foxworth, J W, Willsie, S K, Daus, J C, Owen, R, Flockhart, D A

    Published in Clinical pharmacology and therapeutics (01-08-1996)
    “…Our objective was to study omeprazole as a single-dose oral probe in the determination of CYP2C19 phenotype in black subjects and to determine the correlation…”
    Get more information
    Journal Article
  11. 11

    Roadmap to risk evaluation and mitigation strategies (REMS) success by Balian, John D., Wherry, Janice C., Malhotra, Rachpal, Perentesis, Valerie

    Published in Therapeutic Advances in Drug Safety (01-10-2010)
    “…Medical safety-related risk management is a rapidly evolving and increasingly important aspect of drug approval and market longevity. To effectively meet the…”
    Get full text
    Book Review Journal Article
  12. 12

    Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species by Mahmood, Iftekhar, Balian, John Dikran

    Published in Life sciences (1973) (1996)
    “…The prediction of pharmacokinetic parameters in humans from data obtained in lower animals can be of considerable importance in the process of drug…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Real-Time Assessment of Myocardial Viability in the Catheterization Laboratory Using the Intracoronary Electrograms Recorded by the PTCA Guidewire in Patients With Left Ventricular Dysfunction by Petrucci, Ettore, MD, Balian, Vruyr, MD, Bocchieri, Andrea, PhD

    Published in JACC. Cardiovascular interventions (01-09-2014)
    “…Abstract Objectives This study aimed to determine whether the intracoronary electrograms (IC-EGMs) recorded using a standard percutaneous coronary intervention…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Clinical Relevance and Labeling of Food-Effect Bioavailability (FEB) Studies by Parekh, A., Barsamian, A., Balian, J.D., Lesko, L.

    Published in Clinical pharmacology and therapeutics (01-02-1999)
    “…Clinical Pharmacology & Therapeutics (1999) 65, 174–174; doi:…”
    Get full text
    Journal Article
  17. 17

    Hepatic Impairment (HI) Studies Submitted in New Drug Applications (NDAs) by Mehta, M., Parmelee, T., Balian, J.D., Lesko, L.

    Published in Clinical pharmacology and therapeutics (01-02-1999)
    “…Clinical Pharmacology & Therapeutics (1999) 65, 129–129; doi:…”
    Get full text
    Journal Article
  18. 18

    Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies by Chouela, E N, Abeldaño, A M, Pellerano, G, La Forgia, M, Papale, R M, Garsd, A, Balian, M C, Battista, V, Poggio, N

    Published in Archives of dermatology (1960) (01-06-1999)
    “…To compare the therapeutic efficacy and safety of ivermectin and lindane for the treatment of human scabies. Randomized, prospective, controlled, double-blind,…”
    Get more information
    Journal Article